{
    "nct_id": "NCT06402201",
    "official_title": "Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors",
    "inclusion_criteria": "1. Provision of written informed consent\n2. HLA-A*02:01 positive\n3. MAGE-A4 positive tumor\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1\n5. Selected advanced solid tumors\n6. Relapsed from, refractory to, or intolerant of standard therapy\n7. Measurable disease per RECIST v1.1\n8. Adequate organ function\n9. If applicable, must agree to use highly effective contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Symptomatic or untreated central nervous system metastasis\n2. Inadequate washout from prior anticancer therapy\n3. Significant ongoing toxicity from prior anticancer treatment\n4. Recent surgery\n5. Clinically significant cardiac disease\n6. Active infection requiring systemic antibiotic treatment\n7. Human immunodeficiency virus (HIV) at risk of acquired immunodeficiency syndrome (AIDS)-related outcomes\n8. Active hepatitis B virus (HBV) or hepatitis C virus (HBC)\n9. Ongoing treatment with systemic steroids or other immunosuppressive therapies\n10. Significant secondary malignancy\n11. History of chronic or recurrent active autoimmune disease requiring treatment\n12. Uncontrolled intercurrent illness\n13. Pregnancy or lactation.",
    "miscellaneous_criteria": ""
}